Cargando…

Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD‐L1

Despite their potent antitumor activity, clinical application of immune checkpoint inhibitors has been significantly limited by their poor response rates (<30%) in cancer patients, primarily due to immunosuppressive tumor microenvironments. As a representative immune escape mechanism, cancer‐deri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Jung Min, Lee, Chan‐Hyeong, Son, Soyoung, Kim, Chan Ho, Lee, Jae Ah, Ko, Hyewon, Shin, Sol, Song, Seok Ho, Park, Seong‐Sik, Bae, Ju‐Hyun, Park, Ju‐Mi, Choe, Eun‐Ji, Baek, Moon‐Chang, Park, Jae Hyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844465/ https://www.ncbi.nlm.nih.gov/pubmed/34927389 http://dx.doi.org/10.1002/advs.202103245

Ejemplares similares

Reply to ‘Sulfisoxazole does not inhibit the secretion of small extracellular vesicles’
por: Lee, Chan-Hyeong, et al.
Publicado: (2021)

Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A
por: Im, Eun-Ju, et al.
Publicado: (2019)

Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1
por: Choe, Eun-Ji, et al.
Publicado: (2022)

Methionine deficiency facilitates antitumour immunity by altering m(6)A methylation of immune checkpoint transcripts
por: Li, Ting, et al.
Publicado: (2023)

Sulfisoxazole does not inhibit the secretion of small extracellular vesicles
por: Fonseka, Pamali, et al.
Publicado: (2021)

Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1
por: Park, Seong-Sik, et al.
Publicado: (2022)

Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
por: Meng, Fanqiang, et al.
Publicado: (2022)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
por: An, Ho Jung, et al.
Publicado: (2021)

Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1
por: Lee, Chan-Hyeong, et al.
Publicado: (2022)

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
por: Won, Ji Eun, et al.
Publicado: (2022)

Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
por: Leclerc, Marine, et al.
Publicado: (2019)

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
por: Lee, Won Suk, et al.
Publicado: (2020)

Repurposing of Antibiotic Sulfisoxazole Inhibits Lipolysis in Pre-Clinical Model of Cancer-Associated Cachexia
por: Chitti, Sai V., et al.
Publicado: (2021)

Inactivated vaccine with glycyrrhizic acid adjuvant elicits potent innate and adaptive immune responses against foot-and-mouth disease
por: Shin, Seokwon, et al.
Publicado: (2023)

Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors
por: Kim, Hye Ryeon, et al.
Publicado: (2022)

In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade
por: Mao, Chenkai, et al.
Publicado: (2022)

Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome
por: Lee, Jang Hyuck, et al.
Publicado: (2021)

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
por: Jeong, Sun Young, et al.
Publicado: (2023)

DNA immunization of Mycobacterium tuberculosis resuscitation-promoting factor B elicits polyfunctional CD8(+) T cell responses
por: Lee, Jino, et al.
Publicado: (2014)

Left Hemitruncus Treated Along with Ventricular Septal Defect in a Neonate
por: Lee, Jun Hee, et al.
Publicado: (2020)

Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
por: Lee, Choong-kun, et al.
Publicado: (2022)

Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy
por: Ying, Honggang, et al.
Publicado: (2022)

STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody
por: Lee, Ji-Sun, et al.
Publicado: (2015)

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
por: Lee, Yun-Gyoo, et al.
Publicado: (2021)

DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
por: Dan, Huimin, et al.
Publicado: (2019)

Bicarbonate transport as regulator of antitumour immunity in pancreatic cancer
por: Kay, Emily J., et al.
Publicado: (2023)

Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
por: von Roemeling, Christina A., et al.
Publicado: (2020)

Zika virus baculovirus-expressed envelope protein elicited humoral and cellular immunity in immunocompetent mice
por: Shin, Minna, et al.
Publicado: (2022)

Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases
por: Sullivan, Kevin M, et al.
Publicado: (2023)

Draft genome sequence of alcohol-tolerant bacteria Pediococcus acidilactici strain K3
por: Park, Gun-Seok, et al.
Publicado: (2016)

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
por: Lee, Jiyun, et al.
Publicado: (2020)

Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
por: Lee, Seon-Mi, et al.
Publicado: (2023)

A classical swine fever virus E2 fusion protein produced in plants elicits a neutralizing humoral immune response in mice and pigs
por: Park, Youngmin, et al.
Publicado: (2020)

Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
por: Park, Young-Jun, et al.
Publicado: (2018)

Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach
por: Song, Chorog, et al.
Publicado: (2021)

Machine Learning Predictor of Immune Checkpoint Blockade Response in Gastric Cancer
por: Sung, Ji-Yong, et al.
Publicado: (2022)

The HSP70-fused foot-and-mouth disease epitope elicits cellular and humoral immunity and drives broad-spectrum protective efficacy
por: Jo, Hyundong, et al.
Publicado: (2021)

Mincle and STING-Stimulating Adjuvants Elicit Robust Cellular Immunity and Drive Long-Lasting Memory Responses in a Foot-and-Mouth Disease Vaccine
por: Lee, Min Ja, et al.
Publicado: (2019)

The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade
por: Park, Jang Hyun, et al.
Publicado: (2022)

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response
por: Gilabert-Oriol, Roger, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ra423lmrlm287q0cn2nbto1h4u